[Clinical characterization of 61 cases of diffuse large B-cell lymphoma with different prognosis].
Qian
Q
Wang
Xu-Dong
XD
Wei
Qing-Song
QS
Yin
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004268:DNA-Binding Proteins / Q000378:metabolism; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D018858:Germinal Center / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D050835:Interferon Regulatory Factors / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification* / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000378:metabolism; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D051560:Proto-Oncogene Proteins c-bcl-6; D014750:Vincristine / Q000627:therapeutic use; D000099218:Interferon Regulatory Factor-4
D003520:Cyclophosphamide; D004268:DNA-Binding Proteins; D004317:Doxorubicin; D050835:Interferon Regulatory Factors; D015260:Neprilysin; D011241:Prednisone; D051560:Proto-Oncogene Proteins c-bcl-6; D014750:Vincristine; D000099218:Interferon Regulatory Factor-4; C084103:BCL6 protein, human